Summary of Intensity Therapeutics Q2 2026 Earnings Call

1Key Financial Results and Metrics

Research and Development Expenses: $1.8 million for Q2 2026, up 19% from $1.5 million in Q2 2025, primarily due to increased clinical trial costs.

Clinical Trial Expenses: $1.2 million, reflecting costs associated with the Phase III INVINCIBLE-3 study, which resumed limited enrollment after a pause.

General and Administrative Expenses: $1.3 million, a 7% increase from $1.2 million in the prior year, driven by higher employee compensation and other expenses.

Net Loss: $3 million for Q2 2026, compared to $2.5 million in Q2 2025, representing a 19% increase in losses.

Cash Position: $9.5 million as of June 30, 2026, with an additional $1.3 million raised post-quarter under an at-the-market facility.

2Strategic Updates and Business Highlights

Clinical Trials:

The INVINCIBLE-3 study is set to resume patient enrollment in limited U.S. sites after a funding-related pause. The trial aims to assess INT230-6 against standard treatments for soft tissue sarcomas.

The INVINCIBLE-4 study for early-stage triple-negative breast cancer has resumed in Switzerland and opened a site in France, targeting completion of enrollment by the end of 2027.

Clinical Data: Preliminary results from INVINCIBLE-4 show a 71% pathologic complete response (pCR) in patients receiving INT230-6 before standard care, compared to 42% in the control group.

Publications: A significant study on INT230-6 was published in the journal eBioMedicine, enhancing the company's visibility in the oncology community.

Partnership Discussions: The company is exploring potential partnerships following positive interest expressed at the BIO International Convention.

3Forward Guidance and Outlook

Cash Burn: Estimated at approximately $1 million per month for the second half of 2026, with a total of $30 million needed to complete the INVINCIBLE-3 study over the next several years.

Enrollment Plans: Limited site activations will proceed as additional capital is raised, with a focus on maintaining operational flexibility.

4Bad News, Challenges, or Points of Concern

Funding Constraints: The company has indicated that it does not currently have sufficient capital to fully restart all study sites for INVINCIBLE-3, necessitating further fundraising efforts.

Increased Net Losses: The rise in net losses raises concerns about financial sustainability, especially given the high cash burn rate.

Regulatory Complexity: The submission process for INVINCIBLE-3 in Europe is complicated by the need for extensive documentation across multiple countries, potentially delaying progress.

5Notable Q&A Insights

Capital Requirements: Management highlighted a need for an additional $30 million to fully support the INVINCIBLE-3 study, indicating current funding is insufficient for a full restart.

Patient Enrollment: There is strong interest from clinical sites to resume enrollment for INVINCIBLE-3, driven by the lack of effective treatments in the second- and third-line settings.

Regulatory Challenges: The complexity of the European submission process for INVINCIBLE-3 is a significant hurdle compared to the simpler process for INVINCIBLE-4.

Partnership Opportunities: The company is open to various partnership formats, including global and regional rights, to expedite the development and distribution of its therapies. Overall, while Intensity Therapeutics is making progress in its clinical trials and has improved its cash position, it faces significant financial and operational challenges that must be addressed to sustain its development efforts.